9/27/26
PT Bundamedik Tbk (BMHS.JK) Thesis The recent strategic partnership and expansion plans are expected to drive significant revenue growth, improving investor sentiment.
★ Analysts see FY2026 revenue reaching $1.88T — +16.3% growth in a single year.
Why Revenue Could Accelerate 01 Recent partnership with a major insurance provider is expected to increase patient volumes by 15% over the next year. 02 Expansion into underserved regions of Indonesia projected to add $50M in annual revenue by FY27. 03 Implementation of a new electronic health record system expected to reduce operational costs by 10% over the next two years. 04 Digital health transformation 05 Expansion of healthcare access in emerging markets 06 Changes in healthcare regulations impacting reimbursement rates 07 Patient volume fluctuations due to seasonal health trends 08 Expansion of service offerings or new facility openings 149 168 186 205 224 200.00 BMHS.JK Daily 200.00 Apr '26 Jun '26 Aug '26 Sep '26
My Notes "Our new partnerships will enhance patient access and drive growth in previously untapped markets." Moat: Bundamedik's established brand and network create a strong competitive advantage in patient retention and acquisition. value - the company’s low Price/Book ratio suggests it may be undervalued relative to its assets. Rising interest rates could increase financing costs for capital expenditures, impacting expansion plans and profitability. Watch on earnings: Patient admission rates, Revenue growth rate, Operating margin. One Sentence Summary: The bull case is simple: analysts see revenue climbing from $1.88T to $2.08T as recent partnership with a major insurance provider is expected to increase patient volumes by 15% over the next year.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
